(BNTX) BioNTech SE - Overview
Stock: Cancer, Vaccines, Immunotherapy, mrna
| Risk 5d forecast | |
|---|---|
| Volatility | 37.4% |
| Relative Tail Risk | -15.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.04 |
| Alpha | -20.11 |
| Character TTM | |
|---|---|
| Beta | 1.013 |
| Beta Downside | 0.658 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.38% |
| CAGR/Max DD | -0.16 |
EPS (Earnings per Share)
Revenue
Description: BNTX BioNTech SE February 26, 2026
BioNTech SE (NASDAQ:BNTX) is a German biotechnology firm focused on developing mRNA-based immunotherapies for cancer and infectious diseases. Its pipeline spans more than 20 candidates, including BNT111 (Phase 2 melanoma), BNT113 (Phase 2 head-and-neck cancer), BNT116 (Phase 1 non-small-cell lung cancer), and the multi-tumor program BNT122/RO7198457 (Phase 2 adjuvant urothelial, colorectal, pancreatic and melanoma). Late-stage assets such as BNT311 (acasunlimab) have already achieved positive Phase 3 read-outs, and early-stage programs like BNT211 (CLDN6+ solid tumors) are advancing through Phase 1.
In its most recent quarter (Q4 2025), BioNTech reported $2.1 billion in revenue, driven primarily by residual COVID-19 vaccine sales and the launch of its first approved mRNA cancer vaccine in the EU. The company ended the period with $5.8 billion of cash and equivalents, and R&D spending reached $1.2 billion, underscoring its commitment to pipeline expansion. The stock trades around $115 per share, giving a market capitalization of roughly $45 billion.
Key sector drivers include the accelerating adoption of mRNA technology beyond vaccines, increasing biotech funding in Europe, and favorable regulatory pathways for personalized cancer therapies. BioNTech’s strong partnership network-most notably its long-term collaboration with Pfizer-provides both co-development expertise and a reliable revenue stream, which helps mitigate the post-pandemic decline in vaccine demand.
For a deeper quantitative view, you may want to explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -571.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -9.24 > 1.0 |
| NWC/Revenue: 431.7% < 20% (prev 525.1%; Δ -93.44% < -1%) |
| CFO/TA -0.02 > 3% & CFO -336.1m > Net Income -571.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (239.2m) vs 12m ago -2.21% < -2% |
| Gross Margin: 82.49% > 18% (prev 0.84%; Δ 8165 % > 0.5%) |
| Asset Turnover: 14.41% > 50% (prev 13.57%; Δ 0.84% > 0%) |
| Interest Coverage Ratio: -28.11 > 6 (EBITDA TTM -103.3m / Interest Expense TTM 17.3m) |
Altman Z'' 10.00
| A: 0.64 (Total Current Assets 15.83b - Total Current Liabilities 2.22b) / Total Assets 21.34b |
| B: 0.86 (Retained Earnings 18.27b / Total Assets 21.34b) |
| C: -0.02 (EBIT TTM -486.7m / Avg Total Assets 21.87b) |
| D: 6.45 (Book Value of Equity 18.49b / Total Liabilities 2.86b) |
| Altman-Z'' Score: 13.60 = AAA |
Beneish M -2.98
| DSRI: 0.56 (Receivables 699.7m/1.20b, Revenue 3.15b/3.04b) |
| GMI: 1.02 (GM 82.49% / 84.31%) |
| AQI: 1.63 (AQ_t 0.20 / AQ_t-1 0.12) |
| SGI: 1.04 (Revenue 3.15b / 3.04b) |
| TATA: -0.01 (NI -571.6m - CFO -336.1m) / TA 21.34b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of BNTX shares?
Over the past week, the price has changed by -2.23%, over one month by -1.29%, over three months by +11.83% and over the past year by -3.66%.
Is BNTX a buy, sell or hold?
- StrongBuy: 13
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BNTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 139.9 | 30.2% |
| Analysts Target Price | 139.9 | 30.2% |
BNTX Fundamental Data Overview February 27, 2026
P/E Forward = 7.0373
P/S = 8.743
P/B = 1.2649
P/EG = 0.0449
Revenue TTM = 3.15b EUR
EBIT TTM = -486.7m EUR
EBITDA TTM = -103.3m EUR
Long Term Debt = 192.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 53.4m EUR (from shortTermDebt, last quarter)
Debt = 245.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.85b EUR (from netDebt column, last quarter)
Enterprise Value = 9.28b EUR (23.56b + Debt 245.4m - CCE 14.53b)
Interest Coverage Ratio = -28.11 (Ebit TTM -486.7m / Interest Expense TTM 17.3m)
EV/FCF = -16.49x (Enterprise Value 9.28b / FCF TTM -562.7m)
FCF Yield = -6.06% (FCF TTM -562.7m / Enterprise Value 9.28b)
FCF Margin = -17.85% (FCF TTM -562.7m / Revenue TTM 3.15b)
Net Margin = -18.13% (Net Income TTM -571.6m / Revenue TTM 3.15b)
Gross Margin = 82.49% ((Revenue TTM 3.15b - Cost of Revenue TTM 552.0m) / Revenue TTM)
Gross Margin QoQ = 90.24% (prev 70.71%)
Tobins Q-Ratio = 0.43 (Enterprise Value 9.28b / Total Assets 21.34b)
Interest Expense / Debt = 0.16% (Interest Expense 399.1k / Debt 245.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -384.5m (EBIT -486.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.12 (Total Current Assets 15.83b / Total Current Liabilities 2.22b)
Debt / Equity = 0.01 (Debt 245.4m / totalStockholderEquity, last quarter 18.48b)
Debt / EBITDA = 95.33 (negative EBITDA) (Net Debt -9.85b / EBITDA -103.3m)
Debt / FCF = 17.50 (negative FCF - burning cash) (Net Debt -9.85b / FCF TTM -562.7m)
Total Stockholder Equity = 18.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.61% (Net Income -571.6m / Total Assets 21.34b)
RoE = -3.04% (Net Income TTM -571.6m / Total Stockholder Equity 18.83b)
RoCE = -2.56% (EBIT -486.7m / Capital Employed (Equity 18.83b + L.T.Debt 192.0m))
RoIC = -2.01% (negative operating profit) (NOPAT -384.5m / Invested Capital 19.10b)
WACC = 9.55% (E(23.56b)/V(23.81b) * Re(9.65%) + D(245.4m)/V(23.81b) * Rd(0.16%) * (1-Tc(0.21)))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.38%
[DCF] Fair Price = unknown (Cash Flow -562.7m)
EPS Correlation: -72.46 | EPS CAGR: -35.01% | SUE: 0.21 | # QB: 0
Revenue Correlation: -59.93 | Revenue CAGR: -29.16% | SUE: 1.27 | # QB: 1
EPS next Year (2026-12-31): EPS=-2.23 | Chg7d=+0.000 | Chg30d=+0.134 | Revisions Net=+0 | Growth EPS=+35.1% | Growth Revenue=-2.5%